Huntington Disease - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Huntington Disease Market Outlook

Thelansis's "Huntington Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Huntington Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Huntington's Disease Overview

Huntington's disease (HD) is a rare, progressive, autosomal dominant neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the HTT gene, resulting in the production of toxic mutant huntingtin (mHTT) protein. The disease is characterized by progressive degeneration of neurons, particularly within the striatum and cerebral cortex, leading to worsening motor dysfunction, cognitive decline, and psychiatric disturbances. Genetic anticipation is commonly observed, with successive generations often experiencing earlier disease onset and increased severity.

Clinically, HD presents with a triad of motor, cognitive, and psychiatric symptoms. Early disease is typically associated with hyperkinetic movements such as chorea, while advanced stages progress toward rigidity, dystonia, impaired coordination, and severe functional decline. Cognitive impairment gradually evolves into subcortical dementia, accompanied by psychiatric manifestations including depression, apathy, anxiety, irritability, and impulsive behavior, significantly impacting patient quality of life and caregiver burden.

Currently, no curative or disease-modifying therapies are approved to halt or reverse disease progression, and management remains primarily symptomatic and supportive. VMAT2 inhibitors, including tetrabenazine and deutetrabenazine, are commonly used to manage chorea, while psychiatric symptoms are addressed through antidepressants, antipsychotics, and multidisciplinary supportive care. Increasing research focus on gene-silencing therapies, RNA-targeted approaches, and disease-modifying strategies is expected to reshape the future treatment landscape for HD.

Key Highlights

• In the USA, diagnosed Huntington's disease cases are projected to increase from approximately 39,486 to 42,458, reflecting a gradually increasing diagnosed patient population.
• HD remains a high unmet need neurodegenerative disorder due to the absence of approved disease-modifying therapies.
• Motor dysfunction, cognitive decline, and psychiatric complications continue to contribute substantially to disease burden and caregiver dependency.
• Emerging gene-targeting and RNA-based therapies are driving significant research and clinical development interest in HD treatment.
• Increasing awareness and improved genetic testing are supporting earlier diagnosis and patient identification.

Market Overview

• The Germany Huntington's disease market is projected to grow from approximately $42 MN to $130 MN, reflecting significant market expansion.
• Market growth is supported by:
• Increasing adoption of symptomatic therapies and multidisciplinary disease management
• Advancing development of gene-silencing and disease-modifying therapeutic approaches
• Rising diagnostic awareness and improved access to genetic testing are contributing to patient pool expansion.
• Future market growth will largely depend on successful commercialization of next-generation disease-modifying therapies targeting mutant huntingtin protein pathways.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• SOM Innovation Biotech SA
• Neurocrine Biosciences
• Skyhawk Therapeutics, Inc.
• Sarepta Therapeutics, Inc.
• Hoffmann-La Roche
• Alnylam Pharmaceuticals
• Supernus Pharmaceuticals, Inc.
• UniQure Biopharma B.V.
• Novartis Pharmaceuticals
• Prilenia
• ExoRNA Bioscience
• Medibiofarma S.L.
• Wave Life Sciences Ltd.
• PTC Therapeutics